Shattuck Labs (STTK) AI Stock Analysis

• Market Cap: $244.89M
• Dividend Yield: N/A
• Average Volume (3M): 550.09K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.24
• Revenue Growth: -84.46%
• EPS Growth: 33.32%
• Country: US
• Employees: 44
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.14
• Shares Outstanding: 63,279,842
• 10 Day Avg. Volume: 553,172
• 30 Day Avg. Volume: 550,087
• PEG Ratio: 0.03
• Price to Book (P/B): 0.77
• Price to Sales (P/S): 10.74
• P/FCF Ratio: -1.01
• Enterprise Value/Market Cap: 0.60
• Enterprise Value/Revenue: 146.03
• Enterprise Value/Gross Profit: -168.82
• Enterprise Value/Ebitda: -2.76
• 1Y Price Target: $8.33
• Price Target Upside: 116.36% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 53 Neutral
• Price Target: $4.50 ▲(16.88% Upside)

The score is held back primarily by weak financial performance (sharp revenue decline, large losses, and significant cash burn), partially offset by low leverage on the balance sheet. Technicals are supportive with an uptrend above major moving averages and positive MACD, while valuation remains unattractive due to negative earnings; the new ATM program adds liquidity flexibility but raises dilution risk.

Positive Factors

Low leverage / strong balance sheet

Extremely low debt relative to equity reduces refinancing and interest risk for a capital-intensive biotech. This structural strength gives management flexibility to fund clinical programs, seek partnerships or absorb setbacks without immediate forced dilution or costly credit constraints over the next several quarters.

Meaningful capital base

A sizeable asset base supports ongoing R&D and clinical operations and provides optionality for licensing, asset sales, or securing collaboration deals. Over a multi-month horizon this capital cushion improves the company’s ability to execute development milestones before requiring urgent external financing.

Partnership and licensing revenue model

A business model centered on collaborations, milestone payments and licensing lets the company leverage larger partners’ commercial and regulatory capabilities. Structurally, this reduces the need for upfront commercialization investment and can provide non-dilutive milestone cash as programs advance.

Negative Factors

Severe revenue decline

A small, volatile top line undermines long-term sustainability: it limits internal funding for trials, weakens negotiating leverage with partners, and increases dependence on external capital. Ongoing revenue shrinkage raises the probability of dilution or program delays absent durable new income sources.

High cash burn

Sustained negative operating and free cash flow at scale requires repeated external financing or large milestone receipts. This persistent burn constrains ability to run multiple programs, elevates dilution risk, and forces management to prioritize short-term runway over broader long-term R&D initiatives.

Large ongoing losses and negative ROE

Deep, persistent losses and strongly negative ROE indicate the company is destroying shareholder capital. Structurally, this pressures future investment returns, makes equity funding less attractive, and increases the likelihood of dilutive financing or strategic asset sales to shore up capital for ongoing development.

Shattuck Labs Business Overview & Revenue Model

Company Description

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.

How the Company Makes Money

Shattuck Labs generates revenue primarily through partnerships and collaborations with larger pharmaceutical companies, which provide funding for research and development in exchange for rights to commercialize products developed from their technology. Additionally, the company may receive milestone payments as specific development targets are met during the clinical trial phases. Another key revenue stream could come from licensing agreements, where Shattuck allows other companies to use its proprietary technologies in their own drug development efforts. Sales of any successfully developed therapeutics, once they are approved by regulatory bodies, will also contribute to the company’s earnings. Strategic collaborations with industry leaders enhance the company’s financial growth and provide access to broader markets.

Shattuck Labs Financial Statement Overview

Summary

Overall fundamentals are weak: revenue is very small and fell sharply (TTM down ~66.6%), profitability is deeply negative (TTM EBIT about -$57.8M; net loss about -$54.9M), and cash burn is heavy (TTM operating/FCF about -$48.8M). The main offset is a comparatively strong balance sheet with very low debt (~$1.8M) versus equity (~$93.2M).

Income Statement

TTM (Trailing-Twelve-Months) revenue fell sharply to $1.0M (down ~66.6%), highlighting meaningful top-line volatility. Profitability remains very weak, with deeply negative operating results (TTM EBIT of about -$57.8M) and a large net loss (about -$54.9M), implying the cost base is far ahead of current revenue. A relative positive is that gross margin has improved versus prior years (TTM ~36% vs. negative in some earlier periods), but overall losses and inconsistent revenue trajectory keep the income statement score low.

Balance Sheet

Leverage appears modest, with total debt of ~$1.8M against stockholders’ equity of ~$93.2M in TTM (very low debt relative to equity), which is a balance-sheet strength for a biotech business. Total assets are ~$100.3M, providing a meaningful capital base. The key weakness is persistent negative returns on equity (TTM return on equity around -74%), reflecting ongoing losses that continue to erode shareholder value over time despite low leverage.

Cash Flow

Cash burn remains heavy: TTM operating cash flow is about -$48.8M and free cash flow about -$48.8M, indicating the business is still funding operations through external capital rather than internally generated cash. Free cash flow deterioration versus the prior period (TTM free cash flow growth about -12.7%) adds pressure. A modest positive is that free cash flow roughly tracks net loss (free cash flow to net income ~1.0), suggesting losses are largely mirrored by cash usage rather than being driven by large non-cash gains.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.00M	5.72M	1.66M	652.00K	30.02M	9.93M
Gross Profit	-865.00K	5.72M	-2.38M	652.00K	28.64M	-27.55M
EBITDA	-52.82M	-76.74M	-87.92M	-100.26M	-43.89M	-36.31M
Net Income	-54.90M	-75.41M	-87.30M	-101.94M	-44.97M	-36.60M
Balance Sheet
Total Assets	100.33M	91.05M	159.56M	205.32M	298.58M	348.99M
Cash, Cash Equivalents and Short-Term Investments	42.55M	72.99M	130.63M	161.28M	268.80M	335.45M
Total Debt	1.76M	3.41M	4.20M	4.90M	0.00	0.00
Total Liabilities	7.09M	11.42M	14.86M	29.17M	26.80M	39.13M
Stockholders Equity	93.24M	79.63M	144.71M	176.16M	271.79M	309.86M
Cash Flow
Free Cash Flow	-48.83M	-60.57M	-81.64M	-106.11M	-65.04M	-34.39M
Operating Cash Flow	-48.76M	-60.52M	-81.23M	-94.50M	-57.12M	-33.66M
Investing Cash Flow	3.11M	-8.51M	110.86M	49.44M	-10.44M	-146.32M
Financing Cash Flow	44.37M	787.00K	48.62M	171.00K	1.93M	330.87M

Shattuck Labs Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3.85
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For STTK, the sentiment is Positive. The current price of 3.85 is below the 20-day moving average (MA) of 4.32, above the 50-day MA of 3.44, and above the 200-day MA of 1.86, indicating a neutral trend. The MACD of 0.13 indicates Positive momentum. The RSI at 46.94 is Neutral, neither overbought nor oversold. The STOCH value of 12.29 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for STTK.

Shattuck Labs Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PYPD	56 Neutral	$72.81M	-1.63	-390.53%	―	―	61.23%
STTK	53 Neutral	$244.89M	-3.78	-57.84%	―	-84.46%	33.32%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
XLO	49 Neutral	$40.18M	-0.89	-908.28%	―	588.40%	61.76%
ACRV	49 Neutral	$56.48M	-0.85	-50.23%	―	―	21.17%

Shattuck Labs Corporate Events

Shattuck Labs Launches $75 Million At-The-Market Offering

On January 22, 2026, Shattuck Labs, Inc. entered into a sales agreement with Leerink Partners LLC to offer and sell from time to time up to $75 million of its common stock through an at-the-market equity program registered under an effective shelf registration statement. The company is not obligated to sell any shares and may suspend or terminate the program at any time, while Leerink Partners will act as sales agent on mutually agreed terms in exchange for a commission of up to 3% of gross proceeds plus expense reimbursement. Shattuck Labs plans to use any proceeds from this flexible financing vehicle to fund ongoing and planned clinical trials, develop additional product candidates, and support working capital and general corporate needs, potentially strengthening its balance sheet and providing incremental funding capacity for its R&D pipeline.

The most recent analyst rating on (STTK) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Shattuck Labs stock, see the STTK Stock Forecast page.